Sort by
Refine Your Search
-
Listed
-
Category
-
Program
-
Field
-
translational datasets across seven interconnected work packages. The post holder will work under the leadership of Programme Lead, Dr Sheeba Irshad, and in close collaboration with bioinformatics teams
-
, travel for conferences and presentations, as well as contribute to academic publications. The post holder is expected to hold a PhD degree in Bioinformatics, Computer Science or other relevant discipline
-
of bioinformatics tools for RNA sequencing data analysis. Previous and experience with RNA sequencing, including sample preparation. Downloading a copy of our Job Description Full details of the role and the skills
-
birth research Holds a current Home office personal licence Experience in using statistical tools for bioinformatic analyses Downloading a copy of our Job Description Full details of the role and the
-
, travel for conferences and presentations, as well as contribute to academic publications. The post holder is expected to hold a PhD degree in Bioinformatics, Computer Science or other relevant discipline
-
sitting within a leading programme of clinical, health and bioinformatics at the South London and Maudsley (SLaM) Biomedical Research Centre (BRC) and forms a key component of both the Centre
-
discipline. A significant proportion of our research income is for projects within the Health Schools, so experience in a health-related area (e.g. computational biology, bioinformatics, biophysics, medical
-
discipline. A significant proportion of our research income is for projects within the Health Schools, so experience in a health-related area (e.g. computational biology, bioinformatics, biophysics, medical
-
, neuroimaging, neurophysiology, proteomics, transcriptomics, epigenomics, metabolomics, bioinformatics, cell models and animal models. First in man and Phase 2, 3 and 4 clinical trials are also strongly supported
-
, neuroimaging, neurophysiology, proteomics, transcriptomics, epigenomics, metabolomics, bioinformatics, cell models and animal models. First in man and Phase 2, 3 and 4 clinical trials are also strongly supported